360 related articles for article (PubMed ID: 23873756)
21. Interval faecal occult blood testing in a colonoscopy based screening programme detects additional pathology.
Bampton PA; Sandford JJ; Cole SR; Smith A; Morcom J; Cadd B; Young GP
Gut; 2005 Jun; 54(6):803-6. PubMed ID: 15888788
[TBL] [Abstract][Full Text] [Related]
22. Timely follow-up of positive fecal occult blood tests strategies associated with improvement.
Powell AA; Gravely AA; Ordin DL; Schlosser JE; Partin MR
Am J Prev Med; 2009 Aug; 37(2):87-93. PubMed ID: 19524390
[TBL] [Abstract][Full Text] [Related]
23. Adherence to follow-up after a positive fecal occult blood test in an organized colorectal cancer screening program in Korea, 2004-2008.
Choi KS; Lee HY; Jun JK; Shin A; Park EC
J Gastroenterol Hepatol; 2012 Jun; 27(6):1070-7. PubMed ID: 22004224
[TBL] [Abstract][Full Text] [Related]
24. Inappropriate use of the faecal occult blood test outside of the National Health Service colorectal cancer screening programme.
Peacock O; Watts ES; Hanna N; Kerr K; Goddard AF; Lund JN
Eur J Gastroenterol Hepatol; 2012 Nov; 24(11):1270-5. PubMed ID: 22872076
[TBL] [Abstract][Full Text] [Related]
25. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
[TBL] [Abstract][Full Text] [Related]
26. Electronic health record-based triggers to detect adverse events after outpatient orthopaedic surgery.
Menendez ME; Janssen SJ; Ring D
BMJ Qual Saf; 2016 Jan; 25(1):25-30. PubMed ID: 26359272
[TBL] [Abstract][Full Text] [Related]
27. Missed opportunities to initiate endoscopic evaluation for colorectal cancer diagnosis.
Singh H; Daci K; Petersen LA; Collins C; Petersen NJ; Shethia A; El-Serag HB
Am J Gastroenterol; 2009 Oct; 104(10):2543-54. PubMed ID: 19550418
[TBL] [Abstract][Full Text] [Related]
28. Application of Electronic Algorithms to Improve Diagnostic Evaluation for Bladder Cancer.
Murphy DR; Meyer AN; Vaghani V; Russo E; Sittig DF; Richards KA; Wei L; Wu L; Singh H
Appl Clin Inform; 2017 Mar; 8(1):279-290. PubMed ID: 28326433
[TBL] [Abstract][Full Text] [Related]
29. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
30. [Early detection of bowel cancer in occupational surveillance examinations: switching from a guaiak-based to an immunochemical fecal occult blood test].
Webendörfer S; Riemann JF
Dtsch Med Wochenschr; 2014 Jan; 139(3):79-83. PubMed ID: 24089288
[TBL] [Abstract][Full Text] [Related]
31. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH
Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715
[TBL] [Abstract][Full Text] [Related]
32. The view from two sides: a qualitative study of community and medical perspectives on screening for colorectal cancer using FOBT.
Clavarino AM; Janda M; Hughes KL; Del Mar C; Tong S; Stanton WR; Aitken JF; Leggett BA; Newman B
Prev Med; 2004 Sep; 39(3):482-90. PubMed ID: 15313087
[TBL] [Abstract][Full Text] [Related]
33. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates.
Segnan N; Senore C; Andreoni B; Arrigoni A; Bisanti L; Cardelli A; Castiglione G; Crosta C; DiPlacido R; Ferrari A; Ferraris R; Ferrero F; Fracchia M; Gasperoni S; Malfitana G; Recchia S; Risio M; Rizzetto M; Saracco G; Spandre M; Turco D; Turco P; Zappa M;
J Natl Cancer Inst; 2005 Mar; 97(5):347-57. PubMed ID: 15741571
[TBL] [Abstract][Full Text] [Related]
34. Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer.
Bunting PS; Goel V; Williams JI; Iscoe NA
CMAJ; 1999 Jan; 160(1):70-5. PubMed ID: 9934349
[TBL] [Abstract][Full Text] [Related]
35. Is the type of Medicare insurance associated with colorectal cancer screening prevalence and selection of screening strategy?
Schneider EC; Rosenthal M; Gatsonis CG; Zheng J; Epstein AM
Med Care; 2008 Sep; 46(9 Suppl 1):S84-90. PubMed ID: 18725838
[TBL] [Abstract][Full Text] [Related]
36. Application of electronic trigger tools to identify targets for improving diagnostic safety.
Murphy DR; Meyer AN; Sittig DF; Meeks DW; Thomas EJ; Singh H
BMJ Qual Saf; 2019 Feb; 28(2):151-159. PubMed ID: 30291180
[TBL] [Abstract][Full Text] [Related]
37. Colorectal carcinoma screening procedure use among primary care patients.
Lafata JE; Williams LK; Ben-Menachem T; Moon C; Divine G
Cancer; 2005 Oct; 104(7):1356-61. PubMed ID: 16092119
[TBL] [Abstract][Full Text] [Related]
38. Association of FOBT-assessed faecal Hb content with colonic lesions detected in the Florence screening programme.
Ciatto S; Martinelli F; Castiglione G; Mantellini P; Rubeca T; Grazzini G; Bonanomi AG; Confortini M; Zappa M
Br J Cancer; 2007 Jan; 96(2):218-21. PubMed ID: 17211476
[TBL] [Abstract][Full Text] [Related]
39. A population-based estimate of the extent of colorectal cancer screening in Ontario.
Rabeneck L; Paszat LF
Am J Gastroenterol; 2004 Jun; 99(6):1141-4. PubMed ID: 15180738
[TBL] [Abstract][Full Text] [Related]
40. Prostate-specific antigen tests and prostate cancer screening: an update for primary care physicians.
Kell JS
Can J Urol; 2010 Feb; 17 Suppl 1():18-25. PubMed ID: 20170597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
